European Journal of Cancer 213 (2024) 115074
Contents lists available at ScienceDirect
European Journal of Cancer
journal homepage: www.ejcancer.com
Corrigendum to “Indirect comparison of capmatinib treatment from
GEOMETRY mono-1 trial to SOC in German patients with locally advanced
or metastatic NSCLC harboring METex14 skipping mutations” [Eur J
Cancer 207 (2024) 114158]
Anna Kron a,*,1 , Matthias Scheffler a,1, Marcel Wiesweg b,1 , Horst-Dieter Hummel c,1 ,
Jonas Kulhavy c,1, Stefan Gatteloehner d,1 , Jens Kollmeier e,1, Christoph Schubart f,1,
Thorben Groß g,1 , Melanie-Christin Demes h,1, Stefanie Keymel i,1 , Maria Joosten j,1,
Sabine Merkelbach-Bruse k,1 , Christina Bianca Woelwer k,1, Amanda Tufman l,1,
Diego Kauffmann-Guerrero l,1 , Katharina Oeser m , Melanie Zehaczek m, Ulli Jeratsch m,
Juergen Wolf a,1
a
Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
b
Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany
c
Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken and Bavarian Cancer Research Center (BZKF), University
Hospital Würzburg, Würzburg, Germany
d
Department of Pathology, University Hospital Giessen and Marburg, Giessen, Germany
e
Department of Pneumology, Heckeshorn Lung Clinic, Helios Klinikum Emil von Behring, Berlin, Germany
f
Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universita¨t Erlangen-Nürnberg (FAU), Erlangen, Germany
g
Department of Medical Oncology and Pneumology (Internal Medicine VIII), Eberhard Karls University, Tübingen, Germany
h
Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt, Germany
i
Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital Düsseldorf, Medical Faculty of the Heinrich Heine University Düsseldorf,
Düsseldorf, Germany
j
Institute of Pathology, Charit´e – Universit¨atsmedizin Berlin, Berlin, Germany
k
Institute of Pathology, University Hospital and Medical Faculty, University of Cologne, Cologne, Germany
l
Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL),
Munich, Germany
m
Novartis Pharma GmbH, Nuernberg, Germany
The authors removed the study acronym ‘RECAP’ throughout the Berkemeier (IGES Institute) for their support in designing the study
article. and executing the statistical analyses.”
The authors would like to add the following to acknowledgement
The authors would like to apologise for any inconvenience caused.
section of the publication.
DOI of original article: 10.1016/j.ejca.2024.114158.
“The authors thank Dr. Manuela Bamberger, Stephanie Sussmann,
Heidi Kulas, Maciej Rowinski, Guido Schiffhorst, and Fabian
DOI of original article: https://doi.org/10.1016/j.ejca.2024.114158.
* Correspondence to: Center for Integrated Oncology, University Hospital of Cologne, D-50924 Cologne, Germany.
E-mail address: anna.kron@uk-koeln.de (A. Kron).
1
National Network Genomic Medicine (nNGM) Lung Cancer, Germany.
https://doi.org/10.1016/j.ejca.2024.115074
Available online 30 October 2024
0959-8049/© 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-
nc/4.0/).
